Oncocross Co Ltd
382150
Company Profile
Business description
Oncocross Co Ltd is innovating the drug development process through its AI approach for developing treatments for cancers, rare diseases, and intractable diseases, thereby contributing to a healthier world. Its Technology platforms include ONCOCROSS AI Platform, RAPTOR AI, ONCO-RAPTOR AI, and ONCOfind AI.
Contact
Saechang-ro
11, 15, 16th floor
Mapo-gu
Seoul
KORT: +82 28679967
Sector
Technology
Stock type
Sensitive
Industry
Software - Infrastructure
Fiscal Year End
31 December 2025
Employees
31
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.10 | 81.90 | -0.91% |
| CAC 40 | 7,634.89 | 137.08 | -1.76% |
| DAX 40 | 23,645.55 | 419.92 | -1.74% |
| Dow JONES (US) | 44,130.98 | 330.30 | -0.74% |
| FTSE 100 | 9,067.53 | 65.28 | -0.71% |
| HKSE | 24,507.81 | 265.52 | -1.07% |
| NASDAQ | 21,122.45 | 7.23 | -0.03% |
| Nikkei 225 | 40,799.60 | 270.22 | -0.66% |
| NZX 50 Index | 12,729.40 | 94.34 | -0.74% |
| S&P 500 | 6,339.39 | 23.51 | -0.37% |
| S&P/ASX 200 | 8,662.00 | 80.80 | -0.92% |
| SSE Composite Index | 3,559.95 | 13.26 | -0.37% |